How Bayer Secured The Top-Spot In China: An Interview With Liam Condon
This article was originally published in PharmAsia News
Executive Summary
With China set to become the third largest pharmaceutical market in the world by 2011, and the second largest OTC market next year, Bayer Schering Pharma AG is well-positioned to benefit. Larger in China than most of its Western counterparts, with over $750 million in 2008 sales, accounting for an unusually high 4.8% of global health care revenues, Bayer has understood and adapted to the fundamental differences between the Chinese market and those closer to home
You may also be interested in...
On Heels Of U.S. Approval, BMS, Pfizer Launch Eliquis Ahead Of Pradaxa In China
Under a global collaboration, Bristol-Myers Squibb will co-commercialize Eliquis with Pfizer, but it must contend with Boehringer’s Pradaxa, which has a wider label in China.
On Heels Of U.S. Approval, BMS, Pfizer Launch Eliquis Ahead Of Pradaxa In China
Under a global collaboration, Bristol-Myers Squibb will co-commercialize Eliquis with Pfizer, but it must contend with Boehringer’s Pradaxa, which has a wider label in China.
Emerging Markets Earnings Roundup: Bayer And Merck (Part 3)
Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.